CD7 (T-Cell Leukemia Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone C7/511 ]
|Application ||IF, FC|
|Other Accession||924, 186820|
|Isotype||Mouse / IgG2a|
|Other Names||T-cell antigen CD7, GP40, T-cell leukemia antigen, T-cell surface antigen Leu-9, TP41, CD7, CD7|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD7 (T-Cell Leukemia Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Not yet known.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a protein of 40kDa, identified as CD7, a member of the immunoglobulin gene superfamily. Its N-terminal amino acids 1-107 are highly homologous to Ig kappa-L chains whereas the carboxyl-terminal region of the extracellular domain is proline-rich and has been postulated to form a stalk from which the Ig domain projects. CD7 is expressed on the majority of immature and mature T-lymphocytes, and T cell leukemia. It is also found on natural killer cells, a small subpopulation of normal B cells and on malignant B cells. Cross-linking surface CD7 positively modulates T cell and NK cell activity as measured by calcium fluxes, expression of adhesion molecules, cytokine secretion and proliferation. CD7 associates directly with phosphoinositol 3'-kinase. CD7 ligation induces production of D-3 phosphoinositides and tyrosine phosphorylation.
Miwa H, et al. Biological characteristics of CD7(+) acute leukemia. Leuk. Lymphoma. 1996, 21(3-4):239-244. Rabinowich H, et al. Signaling via CD7 molecules on human NK cells. Induction of tyrosine phosphorylation and beta 1 integrin-mediated adhesion to fibronectin J. Immunol. 1994;153(8):3504-3513. | Saxena A, et al. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol. 1998, 58(4):278-84
If you have any additional inquiries please email technical services at email@example.com.